search
Back to results

Efficacy and Safety of Four Escalating Dose Regimens of TPI ASM8 in Patients With Allergic Asthma

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
TPI ASM8
TPI ASM8
TPI ASM8
TPI ASM8
Sponsored by
Pharmaxis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Men and women 18 to 65 years of age
  • Generally good health; steroid naïve (or who have not taken inhaled/oral corticosteroid within last month) mild to moderate, stable, allergic asthma as defined by ATS criteria
  • History of episodic wheeze and shortness of breath
  • Forced expiratory volume in one second (FEV1) at baseline ≥ 70% of the predicted value
  • Able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.

Exclusion Criteria:

  • Significant acute or chronic medical or psychiatric illness
  • Known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks
  • Use of inhaled or oral corticosteroids within the last 30 days, or need for antihistamines within 72 hours of each allergen or methacholine challenge, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting β2-agonist are allowed).

Sites / Locations

  • McMaster University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Dose level No.1

Dose level No.2

Dose level No.3

Dose level No.4

Arm Description

TPI ASM8 1 mg BID

TPI ASM8 2 mg BID

TPI ASM8 4mg BID

TPI ASM8 8 mg Die

Outcomes

Primary Outcome Measures

Sputum eosinophils (%) on Day 4 versus Screening for each dose level.

Secondary Outcome Measures

Safety and tolerability.
Plasma and sputum pharmacokinetic profile at the two highest dose levels.

Full Information

First Posted
January 13, 2009
Last Updated
November 14, 2013
Sponsor
Pharmaxis
search

1. Study Identification

Unique Protocol Identification Number
NCT00822861
Brief Title
Efficacy and Safety of Four Escalating Dose Regimens of TPI ASM8 in Patients With Allergic Asthma
Official Title
A Single Center, Open Label, Stepwise, Dose Profiling Study to Evaluate the Efficacy and Safety of Four Dose Regimens of Inhaled TPI ASM8 in Patients With Allergic Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
April 2009 (undefined)
Primary Completion Date
February 2010 (Actual)
Study Completion Date
February 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pharmaxis

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
During this proposed clinical trial, the investigators intend to evaluate the pharmacodynamic anti-inflammatory properties and safety of TPI ASM8, by investigating the effect on sputum eosinophils and the airway responses during an allergen challenge at different dose levels.
Detailed Description
The early and late asthmatic response were both significantly attenuated by the highest dose of ASM8. The methacholine challenge and other parameters (ECP, mRNA knockdown on CCR3 and B-Chain of IL-3-Il-5 and GMCSF were attenuated by ASM8.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
14 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dose level No.1
Arm Type
Experimental
Arm Description
TPI ASM8 1 mg BID
Arm Title
Dose level No.2
Arm Type
Experimental
Arm Description
TPI ASM8 2 mg BID
Arm Title
Dose level No.3
Arm Type
Experimental
Arm Description
TPI ASM8 4mg BID
Arm Title
Dose level No.4
Arm Type
Experimental
Arm Description
TPI ASM8 8 mg Die
Intervention Type
Drug
Intervention Name(s)
TPI ASM8
Other Intervention Name(s)
ASM8
Intervention Description
4 mg/mL, 1 mg BID for 4 days
Intervention Type
Drug
Intervention Name(s)
TPI ASM8
Other Intervention Name(s)
ASM8
Intervention Description
4 mg/mL, 2 mg BID for 4 days
Intervention Type
Drug
Intervention Name(s)
TPI ASM8
Other Intervention Name(s)
ASM8
Intervention Description
4 mg/mL, 4 mg BID for 4 days
Intervention Type
Drug
Intervention Name(s)
TPI ASM8
Other Intervention Name(s)
ASM8
Intervention Description
4 mg/mL, 8 mg OD for 4 days
Primary Outcome Measure Information:
Title
Sputum eosinophils (%) on Day 4 versus Screening for each dose level.
Time Frame
7 and 24 hrs post-allergen challenge
Secondary Outcome Measure Information:
Title
Safety and tolerability.
Time Frame
Throughout the study
Title
Plasma and sputum pharmacokinetic profile at the two highest dose levels.
Time Frame
Dose level 3 and 4

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Men and women 18 to 65 years of age Generally good health; steroid naïve (or who have not taken inhaled/oral corticosteroid within last month) mild to moderate, stable, allergic asthma as defined by ATS criteria History of episodic wheeze and shortness of breath Forced expiratory volume in one second (FEV1) at baseline ≥ 70% of the predicted value Able to comprehend and follow all required study procedures; willing and able to sign an informed consent form. Exclusion Criteria: Significant acute or chronic medical or psychiatric illness Known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks Use of inhaled or oral corticosteroids within the last 30 days, or need for antihistamines within 72 hours of each allergen or methacholine challenge, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting β2-agonist are allowed).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rene Pageau, B.Pharm M.Sc
Organizational Affiliation
Topigen Pharmaceuticals Inc.
Official's Role
Study Director
Facility Information:
Facility Name
McMaster University
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8N 3Z5
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of Four Escalating Dose Regimens of TPI ASM8 in Patients With Allergic Asthma

We'll reach out to this number within 24 hrs